News & Updates

Individuals with inflammatory bowel disease (IBD) appear to be at greater risk of developing chronic obstructive pulmonary disease (COPD) and asthma, suggests a study.

A remotely delivered structured weight management programme appears effective and safe in reducing symptoms that matter most among individuals with long COVID (LC) and overweight, findings from the wait-list-controlled open-label ReDIRECT trial suggest.

The prespecified final analysis of the phase III CHOICE-01 trial of toripalimab in combination with chemotherapy shows significant improvement in overall survival (OS) in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) without EGFR/ALK driver mutations.

Using the AppO2, a mobile app designed for the clinical monitoring of patients with chronic obstructive pulmonary disease (COPD) on home oxygen (HO) therapy, helps improve the quality of life of these individuals, reports a study.

In the 7-year update of the phase III ALESIA trial, alectinib outdoes crizotinib for Asian patients with treatment-naïve, advanced or metastatic ALK+ non-small-cell lung cancer (NSCLC).

First-line treatment with osimertinib plus platinum-pemetrexed chemotherapy (CTx) induces significant improvements in progression-free survival (PFS) among Asian patients with EGFR-mutated advanced nonsmall cell lung cancer (NSCLC), which is similar with the results seen in the global population of the FLAURA2 study.